Jon Konti, MD
Ophthalmology · Tempe, AZNPI 1417147141
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,979 of the $14,865 with a category attached, or 60.4%. 25 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 30.1% of the total. Reporting peaked in 2024 at $5,167 and has fallen 61.6% since, to $1,985 in 2025. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $76.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$4K
- Glaukos Corporation$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$2K
- Rxsight Inc$555
- Sun Pharmaceutical Industries Inc.$477
- plus $2K from 19 others
What the payments were for
- Consulting fees$5003%
- Speaking & faculty fees$4,02627%
- Travel & lodging$1,3619%
- Food & beverage$8,97960%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 19 | $4,479 |
| Glaukos Corporation | 39 | $3,271 |
| Johnson & Johnson Surgical Vision, Inc. | 24 | $2,339 |
| Alcon | 32 | $1,504 |
| Rxsight Inc | 9 | $555 |
| Sun Pharmaceutical Industries Inc. | 7 | $477 |
| Dompe US, Inc. | 10 | $389 |
| Novartis | 11 | $268 |
| Oyster Point Pharma, Inc. | 8 | $207 |
| AbbVie(2 entities) | 5 | $204 |
| Biotissue Holdings Inc. | 6 | $203 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $186 |
| Harrow Eye, LLC | 3 | $183 |
| Rayner Intraocular Lenses Limited | 4 | $111 |
| Genentech USA, Inc. | 1 | $81 |
| Carl Zeiss Meditec USA, Inc. | 1 | $74 |
| Heidelberg Engineering, Inc. | 1 | $68 |
| Kala Pharmaceuticals, Inc. | 3 | $64 |
| Mallinckrodt Hospital Products Inc. | 2 | $61 |
| Tarsus Pharmaceuticals, Inc. | 1 | $41 |
| Thea Pharma Inc. | 2 | $33 |
| Tearlab Corp | 1 | $22 |
| Sight Sciences, Inc. | 1 | $20 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $16 |
| Lensar, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$4,000
- TENEO$4,000
- Tecnis 1-piece IOL$1,654
- Tecnis 3-piece IOL$1,654
- Tecnis Symfony IOL$1,654
- Tecnis Symfony Toric IOL$1,654
- iStent inject W$754
- Photrexa$600
- KXL System$493
- iDoseTR$491
- IACCESS$307
- RXSIGHT CONTACT LENS$262
- RXSIGHT INJECTOR CARTRIDGE$262
- RXSIGHT INJECTOR HANDPIECE$262
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$262
- CEQUA$248
- Photrexa Viscous and Photrexa$184
- ARGOS$169
- iDose$158
- LIGHT ADJUSTABLE LENS (LAL)$139
How this compares
$14,865 in reported general payments places this provider in the 90th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $573,223 |
| RestasisCyclosporine | 169 | $162,272 |
| Cyclosporine | 126 | $65,081 |
| LumiganBimatoprost | 33 | $14,860 |
| Prednisolone Acetate | 452 | $14,097 |
| MieboPerfluorohexyloctane/Pf | 15 | $12,658 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $11,158 |
| Fluorometholone | 42 | $4,552 |
| Ketorolac Tromethamine | 123 | $2,167 |
| ValacyclovirValacyclovir Hcl | 31 | $1,590 |
| Latanoprost | 169 | $1,454 |
| Ofloxacin | 128 | $1,321 |
| Timolol Maleate | 103 | $1,129 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $732 |
| MoxifloxacinMoxifloxacin Hcl | 45 | $700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $389 | $573,22312 claims |
| AbbVieRestasis, Lumigan | $204 | $177,132202 claims |
| Bausch & Lomb Americas Inc.Miebo | $4,479 | $12,65815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Tempe
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Shamil PatelGlendale$116K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
- George ReissGlendale$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.